Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2416 (LINC02416) is a long non-coding RNA (lncRNA), meaning it is transcribed from DNA but does not encode a protein. LINC02416 is primarily annotated as a gene locus that produces a non-coding RNA transcript, and it is classified among lncRNAs that may regulate gene expression at various levels including chromatin modification, transcription, and post-transcriptional processing[1][2][4]. Functionally, LINC02416 has been identified through transcriptomic analyses as being differentially expressed in several cancers, notably hepatocellular carcinoma and cutaneous melanoma, where it forms part of multi-lncRNA prognostic signatures for cancer risk stratification and immune landscape characterization[2][4]. There is currently no evidence that LINC02416 encodes a receptor, enzyme, transporter, or is directly "targetable" by drugs; rather, it may serve as a prognostic biomarker. There are no known drugs targeting LINC02416, nor are there established mechanisms of drug action or associated safety concerns specific to this lncRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2416 (LINC02416).